Cord injection may curb deadly Post-Birth bleeding
NCT ID NCT07436286
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether giving an extra dose of oxytocin directly into the umbilical vein, along with standard care, could reduce blood loss after childbirth. Over 400 women having a vaginal delivery took part. The goal was to see if this simple, low-cost method could help prevent postpartum hemorrhage, a leading cause of maternal death.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- oxytocin
- What this could lead to
- If effective, this simple addition to standard care could reduce dangerous bleeding after childbirth, especially in low-resource settings.
- What could go wrong
- This is a single completed study with 416 participants. Results may not apply to all settings, and the intervention adds a step to standard care that may not always be feasible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
416 people
The number who actually took part.
- Started
-
Feb 2018
- Finished
-
Aug 2019
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 35 years
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Pregnant women aged 18 to 35 years Singleton live pregnancy Gestational age between 37 and 42 weeks Vaginal delivery Parity between 1 and 4 Haemoglobin concentration of 10 g/dl or higher before delivery No identifiable risk factors for postpartum haemorrhage Willing and able to provide written informed consent Exclusion Criteria: Blood pressure ≥140/90 mmHg Placenta previa Placental abruption History of vaginal bleeding in the index pregnancy Previous caesarean section or any uterine scar Coagulation disorders Instrumental delivery Haemoglobin concentration below 10 g/dl Multiple gestation Fibroids coexisting with pregnancy Genital tract lacerations or bleeding episiotomy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Postpartum hemorrhage (PPH) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ahamadu Bello University Teachinh Hospital
Zaria, Kaduna State, Nigeria
More trials for these conditions
Other studies related to the condition(s) this trial covers.